問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

陳彥豪
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

142Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳彥豪

List

264Cases

2025-02-03 - 2029-12-23

Not yet recruiting
A phase 3 randomized, double-blind, placebo-controlled trial compared TPST-1120 with Atezolizumab plus Bevacizumab to placebo plus Atezolizumab plus Bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma (HCC) who had not received systemic therapy.

  • Condition/Disease

    ● Overall survival (OS) is defined as the time elapsed from random assignment until death from any cause.

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2017-01-20 - 2025-08-15

Phase III

Completed
A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)

  • Condition/Disease

    Head and Neck Neoplasms

  • Test Drug

    Keytruda

Participate Sites
7Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

楊慕華
Taipei Veterans General Hospital

Division of Radiation Therapy

2025-08-20 - 2029-02-17

Phase III

Active
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung (NSCLC)

  • Test Drug

    凍晶注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-09-10 - 2028-06-13

Phase I

Completed
A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  • Condition/Disease

    Advanced Clear Cell Renal Cell Carcinoma

  • Test Drug

    凍晶注射劑 膜衣錠

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    膠囊劑 靜脈輸注液 靜脈輸注液 膠囊劑

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2030-02-01

Phase III

Active
A multicenter, randomized, open-label, phase III trial (DESTINY-Gastric05) evaluating trastuzumab Deruxtecan (Enhertu®) with chemotherapy (with or without pembrolizumab) versus chemotherapy with or without trastuzumab as first-line treatment for patients with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

  • Condition/Disease

    HER2-positive gastric cancer or gastroesophageal junction cancer

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd)

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    注射劑 皮下注射劑 注射劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2031-12-31

Phase III

Active
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

  • Condition/Disease

    Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    凍晶乾燥注射劑 注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2025-03-01 - 2028-03-31

Phase I/II

Active
An open-label, multi-group, phase 1b/2 trial evaluating the safety, efficacy, and optimal dose of Telisotuzumab Adizutecan in combination with a PD-1 immune checkpoint inhibitor in treatment-naïve patients with untreatable genetic mutations in advanced or metastatic non-squamous non-small cell lung cancer (AndroMETa-Lung-536).

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
9Sites

Recruiting9Sites

2025-04-01 - 2032-12-31

Active
A phase 3, multicenter, double-blind, placebo-controlled trial evaluating the efficacy and safety of olomorisabin in combination with standard-of-care immunotherapy in participants with resected or unresectable KRAS G12C-mutant non-small cell lung cancer – SUNRAY-02

  • Condition/Disease

    Part A: Does adding olomorasib to pembrolizumab, compared to placebo and pembrolizumab, prolong disease-free survival (DFS) in participants with pathologically confirmed resected stage II-IIIB NSCLC? (These participants had a KRAS G12C mutation, PD-L1 performance ranging from 0% to 100%, and had previously received chemotherapy.) Part B: Does adding olomorasib to durvalumab, compared to placebo and durvalumab, prolong disease-free survival (PFS) in participants with pathologically confirmed unresectable stage III non-small cell lung cancer? (These participants had a KRAS G12C mutation, had not experienced disease progression after concurrent platinum-based chemotherapy and radiation therapy, and had PD-L1 performance ranging from 0% to 100%.)

  • Test Drug

    Durvalumab Olomorasib PembrolizumabDurvalumab

Participate Sites
18Sites

Recruiting18Sites

1 2 3 4 5 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB